Substituted indole Mcl-1 inhibitors: a patent evaluation (WO2015148854A1)

References

• Shamas-Din A, Kale J, Leber B, et al. Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb Perspect Biol. 2013;5:a008714.
   PubMed Web of Science ®Google Scholar
• Danial NN. BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin Cancer Res. 2007;13:7254–7263.
   PubMed Web of Science ®Google Scholar
• Brenner C, Grimm S. The permeability transition pore complex in cancer cell death. Oncogene. 2006;25:4744–4756.
   PubMed Web of Science ®Google Scholar
• Dewson G, Kratina T, Czabotar P, et al. Bak activation for apoptosis involves oligomerization of dimers via their α6 helices. Mol Cell. 2009;36:696–703.
   PubMed Web of Science ®Google Scholar
• Aouacheria A, Combet C, Tompa P, et al. Redefining the BH3 death domain as a ‘short linear motif’. Trends Biochem Sci. 2015;40:736–748.
   PubMed Web of Science ®Google Scholar
• Rautureau GJ, Day CL, Hinds MG. Intrinsically disordered proteins in Bcl-2 regulated apoptosis. Int J Mol Sci. 2010;11:1808–1824.
   PubMed Web of Science ®Google Scholar
• Hinds MG, Smits C, Fredericks-Short R, et al. Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets. Cell Death Differ. 2007;14:128–136.
   PubMed Web of Science ®Google Scholar
• Rogers JM, Wong CT, Clarke J. Coupled folding and binding of the disordered protein PUMA does not require particular residual structure. J Am Chem Soc. 2014;136:5197–5200.
   PubMed Web of Science ®Google Scholar
• Huang Z. Bcl-2 family proteins as targets for anticancer drug design. Oncogene. 2000;19:6627–6631.
   PubMed Web of Science ®Google Scholar
• Weyhenmeyer B, Murphy AC, Prehn JH, et al. Targeting the anti-apoptotic Bcl-2 family members for the treatment of cancer. Exp Oncol. 2012;34:192–199.
   PubMedGoogle Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–208.
   PubMed Web of Science ®Google Scholar
• No authors listed. Venetoclax approved for CLL. Cancer Discov. 2016;6:564.
   Web of Science ®Google Scholar
• Craig RW. MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia. 2002;16:444–454.
   PubMed Web of Science ®Google Scholar
• Thomas LW, Lam C, Edwards SW. Mcl-1; the molecular regulation of protein function. FEBS Lett. 2010;584:2981–2989.
   PubMed Web of Science ®Google Scholar
• Perciavalle RM, Opferman JT. Delving deeper: MCL-1’s contributions to normal and cancer biology. Trends Cell Biol. 2013;23:22–29.
   PubMed Web of Science ®Google Scholar
• Fire E, Gullá SV, Grant RA, et al. Mcl-1-Bim complexes accommodate surprising point mutations via minor structural changes. Protein Sci. 2010;19:507–519.
   PubMed Web of Science ®Google Scholar
• Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17:393–403.
   PubMed Web of Science ®Google Scholar
• Willis SN, Chen L, Dewson G, et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005;19:1294–1305.
   PubMed Web of Science ®Google Scholar
• Dutta S 1, Gullá S, Chen TS, et al. Determinants of BH3 binding specificity for Mcl-1 versus Bcl-xL. J Mol Biol. 2010;398:747–762.
   PubMed Web of Science ®Google Scholar
• Czabotar PE 1, Lee EF, van Delft MF, et al. Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci U S A. 2007;104:6217–6222.
   PubMed Web of Science ®Google Scholar
• Mojsa B, Lassot I, Desagher S. Mcl-1 ubiquitination: unique regulation of an essential survival protein. Cells. 2014;3:418–437.
   PubMed Web of Science ®Google Scholar
• Schwickart M, Huang X, Lill JR, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature. 2010;463:103–107.
   PubMed Web of Science ®Google Scholar
• Rinkenberger JL, Horning S, Klocke B, et al. Mcl-1 deficiency results in peri-implantation embryonic lethality. Genes Dev. 2000;14:23–27.
   PubMed Web of Science ®Google Scholar
• Opferman JT, Iwasaki H, Ong CC, et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science. 2005;307:1101–1104.
   PubMed Web of Science ®Google Scholar
• Perciavalle RM, Stewart DP, Koss B, et al. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol. 2012;14:575–583.
   PubMed Web of Science ®Google Scholar
• Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463:899–905.
   PubMed Web of Science ®Google Scholar
• Kelly GL, Grabow S, Glaser SP, et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev. 2014;28:58–70.
   PubMed Web of Science ®Google Scholar
• Glaser SP, Lee EF, Trounson E, et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 2012;26:120–125.
   PubMed Web of Science ®Google Scholar
• Wertz IE, Kusam S, Lam C, et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature. 2011;471:110–114.
   PubMed Web of Science ®Google Scholar
• Wei SH, Dong K, Lin F, et al. Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell. Cancer Chemother Pharmacol. 2008;62:1055–1064.
   PubMed Web of Science ®Google Scholar
• Verhaegen M, Bauer JA, Martín de la Vega C, et al. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res. 2006;66:11348–11359.
   PubMed Web of Science ®Google Scholar
• Touzeau C, Dousset C, Le Gouill S, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t (11; 14) multiple myeloma. Leukemia. 2014;28:210–212.
   PubMed Web of Science ®Google Scholar
• Choudhary GS, Al-Harbi S, Mazumder S, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventingPI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015;6:e1593.
   PubMed Web of Science ®Google Scholar
• Van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1is neutralized. Cancer Cell. 2006;10:389–399.
   PubMed Web of Science ®Google Scholar
• Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421–3428.
   PubMed Web of Science ®Google Scholar
• Yecies D, Carlson NE, Deng J, et al. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood. 2010;115:3304–3313.
   PubMed Web of Science ®Google Scholar
• Li X, Keskin O, Ma B, et al. Protein-protein interactions: hot spots and structurally conserved residues often locate in complemented pockets that pre-organized in the unbound states: implications for docking. J Mol Biol. 2004;344:781–795.
   PubMed Web of Science ®Google Scholar
• Nguyen M, Marcellus RC, Roulston A, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Pro Natl Acad Sci USA. 2007;104:19512–19517.
   PubMed Web of Science ®Google Scholar
• Gemin X Biotechnologies, Inc. Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases. WO2004106328A1. 2004.
   Google Scholar
• O’Brien SM, Claxton DF, Crump M, et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood. 2009;113:299–305.
   PubMed Web of Science ®Google Scholar
• Vogler M, Weber K, Dinsdale D, et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ. 2009;16:1030–1039.
   PubMed Web of Science ®Google Scholar
• Enyedy IJ, Ling Y, Nacro K, et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem. 2001;44:4313–4324.
   PubMed Web of Science ®Google Scholar
• University of Michigan. Small molecule antagonists of Bcl-2 family proteins. WO2002097053A2. 2002. US7432304. 2008.
   Google Scholar
• Liu G, Kelly WK, Wilding G, et al. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res. 2009;15:3172–3176.
   PubMed Web of Science ®Google Scholar
• Heist RS, Fain J, Chinnasami B, et al. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol. 2010;5:1637–1643.
   PubMed Web of Science ®Google Scholar
• Wang G, Nikolovska-Coleska Z, Yang CY, et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006;49:6139–6142.
   PubMed Web of Science ®Google Scholar
• Varadarajan S, Vogler M, Butterworth M, et al. Evaluation and critical assessment of putative MCL-1 inhibitors. Cell Death Differ. 2013;20:1475–1484.
   PubMed Web of Science ®Google Scholar
• Wei J, Kitada S, Rega M, et al. Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem. 2009;52:4511–4523.
   PubMed Web of Science ®Google Scholar
• Wei J, Kitada S, Rega MF, et al. Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther. 2009;8:904–913.
   PubMed Web of Science ®Google Scholar
• Wei J, Stebbins JL, Kitada S, et al. BI-97C1, an optically pure apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem. 2010;53:8000–8011.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Jin L, Qian X, et al. Novel Bcl-2 inhibitors: Discovery and mechanism study of small organic apoptosis-inducing agents. Chembiochem. 2007;8:113–121.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Song T, Zhang T, et al. A novel BH3 mimetic S1 potently induces Bax/Bak-dependent apoptosis by targeting both Bcl-2 and Mcl-1. Int J Cancer. 2011;128:1724–1735.
   PubMed Web of Science ®Google Scholar
• Song T, Chang X, Zhang Z, et al. S1, a novel pan-BH3 mimetic, induces apoptosis in Mcl-1-overexpressing cells through Bak. J Pharmacol Sci. 2012;119:330–340.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wu G, Xie F, et al. 3-Thiomorpholin-8-oxo-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile (S1) based molecules as potent, dual inhibitors of B-cell lymphoma 2 (Bcl-2) and myeloid cell leukemia sequence 1 (Mcl-1): structure-based design and structure-activity relationship studies. J Med Chem. 2011;54:1101–1105.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang Z, Song T, et al. Resistance to BH3 mimetic S1 in SCLC cells that up-regulate and phosphorylate Bcl-2 through ERK1/2. Br J Pharmacol. 2013;169:1612–1623.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li Z, Song T, et al. Mechanisms of anti-leukemic activity of the Bcl-2 homology domain-3 mimetic S1. Biomed Pharmacother. 2013;67:583–591.
   PubMed Web of Science ®Google Scholar
• Song T, Li X, Chang X, et al. 3-Thiomorpholin-8-oxo-8H-acenaphtho [1, 2-b] pyrrole-9-carbonitrile (S1) derivatives as pan-Bcl-2-inhibitors ofBcl-2, Bcl-xL and Mcl-1. Bioorg Med Chem. 2013;21:11–20.
   PubMed Web of Science ®Google Scholar
• Song T, Yu X, Liu Y, et al. Discovery of a small-molecule pBcl-2 inhibitor that overcomes pBcl-2-mediated resistance to apoptosis. Chembiochem. 2015;16:757–765.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Liu Y, Song T, et al. An antiapoptotic Bcl-2 family protein index predicts the response of leukemic cells to the pan-Bcl-2 inhibitor S1. Br J Cancer. 2013;108:1870–1878.
   PubMed Web of Science ®Google Scholar
• Song T, Chai G, Liu Y, et al. Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding. Br J Pharmacol. 2016;173:471–483.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Li X, Song T, et al. An anthraquinone scaffold for putative, two-face Bim BH3 α-helix mimic. J Med Chem. 2012;55:10735–10741.
   PubMed Web of Science ®Google Scholar
• Li X, Wang Z, Feng Y, et al. Two-face, two-turn α-helix mimetics based on a cross-acridine scaffold: analogues of the Bim BH3 domain. Chembiochem. 2014;15:1280–1285.
   PubMed Web of Science ®Google Scholar
• Wang Z, Song T, Feng Y, et al. Bcl-2/MDM2 dual inhibitors based on universal pyramid-like α-helical mimetics. J Med Chem. 2016;59:3152–3162.
   PubMed Web of Science ®Google Scholar
• Friberg A, Vigil D, Zhao B, et al. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. J Med Chem. 2013;56:15–30.
   PubMed Web of Science ®Google Scholar
• Pelz NF, Bian Z, Zhao B, et al. Discovery of 2-indole-acylsulfonamide myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods. J Med Chem. 2016;59:2054–2066.
   PubMed Web of Science ®Google Scholar
• Bruncko M, Wang L, Sheppard GS, et al. Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity. J Med Chem. 2015;58:2180–2194.
   PubMed Web of Science ®Google Scholar
• Leverson JD, Zhang H, Chen J, et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis. 2015;6:e1590.
   PubMed Web of Science ®Google Scholar
• Doi K, Li R, Sung SS, et al. Discovery of marinopyrrole a (Maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J Biol Chem. 2012;287:10224–10235.
   PubMed Web of Science ®Google Scholar
• Pandey MK, Gowda K, Doi K, et al. Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells. PLoS One. 2013;8:e78570.
   PubMed Web of Science ®Google Scholar
• Liu G, Poppe L, Aoki K, et al. High-quality NMR structure of human anti-apoptotic protein domain Mcl-1 (171-327) for cancer drug design. PLoS One. 2014;9:e96521.
   Google Scholar
• Abulwerdi FA, Liao C, Mady AS, et al. 3-Substituted-N-(4-Hydroxynaphthalen-1-yl) arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation. J Med Chem. 2014;57:4111–4133.
   PubMed Web of Science ®Google Scholar
• Abulwerdi F, Liao C, Liu M, et al. A novel small-molecule inhibitor of Mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther. 2014;13:565–575.
   PubMed Web of Science ®Google Scholar
• Wei D, Zhang Q, Schreiber JS, et al. Targeting Mcl-1 for Radiosensitization of pancreatic cancers. Transl Oncol. 2015;8:47–54.
   PubMed Web of Science ®Google Scholar
• Cohen NA, Stewart ML, Gavathiotis E, et al. A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival. Chem Biol. 2012;19:1175–1186.
   PubMedGoogle Scholar
• Zhang Z, Song T, Li X, et al. Novel soluble myeloid cell leukemia sequence 1 (Mcl-1) inhibitor (E,E)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (4g) developed using a fragment-based approach. Eur J Med Chem. 2013;59:141–149.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Liu C, Li X, et al. Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors. Eur J Med Chem. 2013;60:410–420.
   PubMed Web of Science ®Google Scholar
• Belmonte MA, Adam A, Borrelli D, et al. Evaluation of Mcl-1 inhibitors in preclinical models of multiple myeloma. Blood. 2014;124:3428.
   Google Scholar
• Zhong Q, Gao W, Du F, et al. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell. 2005;121:1085–1095.
   PubMed Web of Science ®Google Scholar
• Warr MR, Acoca S, Liu Z, et al. BH3-ligand regulates access of Mcl-1 to its E3 ligase. FEBS Lett. 2005;579:5603–5608.
   PubMed Web of Science ®Google Scholar
• Gomez-Bougie P, Menoret E, Juin P, et al. Noxa controls mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1/USP9X interaction. Biochem Biophys Res Commun. 2011;413:460–464.
   PubMed Web of Science ®Google Scholar
• Song T, Wang Z, Ji F, et al. Deactivation of Mcl-1 by dual-function small-molecule inhibitors targeting Bcl-2 homology 3 domain and facilitating Mcl-1 ubiquitination. Angew Chem Int Ed Engl. Forthcoming.
   Google Scholar
• Domina AM, Vrana JA, Gregory MA, et al. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene. 2004;23:5301–5315.
   PubMed Web of Science ®Google Scholar
• Mazumder S, Choudhary GS, Al-Harbi S, et al. Mcl-1 phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. Cancer Res. 2012;72:3069–3079.
   PubMed Web of Science ®Google Scholar
• Liu Y, Xie M, Song T, et al. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1. Pigment Cell Melanoma Res. 2015;28:161–170.
   PubMed Web of Science ®Google Scholar
• Vanderbilt University. Substituted indole Mcl-1 Inhibitors. WO2015148854A1. 2015.
   Google Scholar
• Abbott Laboratories. 7-substituted indole Mcl-1 Inhibitors. WO2008131000A2. 2008.
   Google Scholar
• Abbott Laboratories. 7-nonsubstituted indole Mcl-1 Inhibitors. WO2008130970A1. 2008.
   Google Scholar
• The University of Michigan. Small molecule inhibitors of Mcl-1 and uses thereof. WO2013052943A2. 2013.
   Google Scholar
• The University of Michigan. Small molecule inhibitors of Mcl-1 and uses thereof. WO2015153959A2. 2015.
   Google Scholar
• Dana-Farber Cancer Institute, Inc. Inhibition of Mcl-1 and/or BFL-1/A1. WO2013142281A1. 2013.
   Google Scholar
• The University of California. Mcl-1 antagonists. WO2015134539A1. 2015.
   Google Scholar
• Les Laboratoires Servier. New thienopyrimidine derivatives, a pr5o6cess for their preparation and pharmaceutical compositions containing them. EP2886545A1. 2015.
   Google Scholar
• Amgen Inc. Compounds that inhibit Mcl-1 protein. US20160068545A1. 2016.
   Google Scholar
• Simonin K, N’Diaye M, Lheureux S, et al. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis. Apoptosis. 2013;18:492–508.
   PubMed Web of Science ®Google Scholar
• Lessene G, Czabotar PE, Colman PM. Bcl-2 family antagonists for cancer therapy. Nat Rev Drug Discov. 2008;7:989–1000.
   PubMed Web of Science ®Google Scholar
• Acoca S, Cui Q, Shore GC, et al. Molecular dynamics study of small molecule inhibitors of the Bcl-2 family. Proteins. 2011;79:2624–2636.
   PubMed Web of Science ®Google Scholar
• Yang C-Y, Wang S. Analysis of flexibility and hotspots in Bcl-xL and Mcl-1 proteins for the design of selective small-molecule inhibitors. ACS Med Chem Lett. 2012;3:308–312.
   PubMed Web of Science ®Google Scholar
• V. Bhat, MB. Olenick, BJ Schuchardt, et al. Biophysical basis of the promiscuous binding of Bcl2 apoptotic repressor to BH3 ligands. J Mol Recognit. 2013;26:501–513.
   PubMed Web of Science ®Google Scholar
• Muqbil I, Mohammad RM. Selecting efficacious Bcl-2 family inhibitors for optimal clinical outcome. Ann Transl Med. 2015;3:312.
   PubMedGoogle Scholar
• Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128:1173–1186.
   PubMed Web of Science ®Google Scholar
• Bruncko M, Oost TK, Belli BA, et al. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem. 2007;50:641–662.
   PubMed Web of Science ®Google Scholar